COMPENSATIONINFORMATION FOR NAMED EXECUTIVE OFFICERS
EXHIBIT 10.20
COMPENSATION INFORMATION FOR NAMED EXECUTIVE OFFICERS
The table below provides information regarding the 2009 annual base salary and target percentage for a cash incentive payment for performance in 2009, of each named executive officer of ARYx Therapeutics, Inc.
|
|
|
|
| 2009 Target Cash |
| |
|
|
|
|
| Incentive Payment |
| |
|
|
|
|
| (As% |
| |
|
|
| 2009 Annual Base |
| of 2009 Annual |
| |
| Name and Principal Position |
| Salary |
| Base Salary) |
| |
| Paul Goddard, Ph.D. |
|
|
|
|
| |
| Chairman and Chief Executive Officer |
| $ | 451,000 |
| 75.0 | % |
| Peter G. Milner, M.D. |
|
|
|
|
| |
| President, Research and Development |
| $ | 333,000 |
| 52.5 | % |
| John Varian |
|
|
|
|
| |
| Chief Operating Officer and Chief Financial Officer |
| $ | 324,000 |
| 52.5 | % |
| Pascal Druzgala, Ph.D. |
|
|
|
|
| |
| Vice President and Chief Scientific Officer |
| $ | 283,000 |
| 45.0 | % |
| Daniel Canafax, Pharm.D. |
|
|
|
|
| |
| Vice President and Chief Development Officer |
| $ | 270,000 |
| 45.0 | % |
| David Nagler |
|
|
|
|
| |
| Vice President, Corporate Affairs and Secretary |
| $ | 256,000 |
| 45.0 | % |
